Future Development GoalsEstablished: April, 2021To develop “superior cells” and DDS that can precisely control the function and in vivo fate of the cells for accelerating regenerative medicine.To create a novel and unique research field focusing on “superior cells” by collaboration of researchers with a variety of expertise.Objectives makiya@rs.tus.ac.jp15FacPharmSciSuperior cellK KusamoriFacPharmSciSuperior cellA KikuchiFac Adv EngCell control materialsY AkiyamaInstArtSciBiomaterialsS Goto・T TsuchidaFac Pharm SciCell system analysisH OhshimaFac Pharm SciCell interface scienceFac Pharm SciTissue regenerationT HayataFac Pharm SciBone regenerationC Yamashita・T AkitaFac Pharm SciBrain/lung DDSK TakeuchiJosaiInt UnivTransdermal DDST Hanawa・K HiroseFac Pharm SciCell control materialsT IyodaSanyo-Onoda City UnivImmune regulationHistoryandBackgroundofThisDivisionResearchPurposesandGoalsofThisDivisionMembersandTheirRolesinThisDivisionCell-based therapy and regenerative medicine can be accelerated by applying the drug delivery system (DDS) concept, in which drugs are delivered at the right time, to the right site of action, and in the right amount, to cells administered to patients for disease treatment. Our division aims to develop “superior cells” with extreme functionality and DDS that enhance their functionality.Figure 1 Members and roles of each group.DirectorProfessor,Department of Pharmacy,Faculty of Pharmaceutical SciencesPh.D. DDS research has been conducted at Tokyo University of Science since early days. Our division originated from the DDS Research Division, which was established in 2003 at the Research Institutes for Science and Technology, Tokyo University of Science. In the “Fusion of Regenerative Medicine with DDS Division” which began in 2015, researchers led by Professor Kimiko Makino have conducted collaborative research focusing on regenerative medicine and the development of DDS for intractable diseases. To continue these activities, a predecessor round-table conference on “Superior Cells and DDS Development for Regenerative Medicine” was established in 2020, which was re-established as a division in April 2021. Under the overall goal of accelerating cell-based therapy and regenerative medicine, our division focuses on (1) the development of “superior cells” by functionalizing the cells administered to patients for therapeutic purposes, and (2) the development of DDS that can precisely manipulate the in vivo distribution of cells and other functional molecules. Research objectives also include the development of therapeutic modalities for respiratory, brain, immune, cancer, and bone diseases. The four groups cooperate with each other to accelerate group research.(1) Superior Cell/DDS Development GroupThis group designs and constructs superior cells and develops DDS to control the function and in vivo distribution of cells and other functional bioactive molecules. The goal is to develop “superior cells” that outperform existing cells in terms of cellular functions through (1) the addition of novel functions, (2) the development of multicellular spheroids/organoids, and (3) the use of exosomes and other extracellular vesicles. In addition, various delivery systems will be developed and applied to the above cells, and their usefulness will be tested in animal models.(2) Cell Function Regulation System Development GroupThis group creates novel compounds that regulate cellular functions, and functional materials that can be used in cell-based therapy and regenerative medicine. These compounds and materials are provided to other groups for application and analysis. The data obtained will be used for developing further functional compounds/materials.(3) Physical Property Control/Analysis GroupThis group evaluates the physical properties of the items developed by the superior cell/DDS development group and the cell function regulation system development group, including superior cells, delivery systems, and functional compounds/materials. This group supports the optimization of these items by providing data feedback to the corresponding groups.(4) Cell/Tissue Regeneration GroupThis group investigates the regeneration mechanism of lung, bone and other tissues, and the treatment of diseases of these tissues/organs. In addition, the interaction between superior cells/DDS and the immune system will be analyzed. Figure 1 summarizes the members and roles of each group. This division develops superior cells and DDS regenerative medicine by establishing organic relationships among the division members in pursuit of a new level of collaboration.[Superior cell/DDS development group]M Nishikawa･S Itakura[Cell function regulation system development group][Physical property control/analysis group][Cell/tissue regeneration group]Y Isohama・K MurakamiMakiya NishikawaDevelopment of superior cells and DDS for accelerating regenerative medicineDivision of Superior Cells and DDS Development for Regenerative Medicine
元のページ ../index.html#15